Company intelligence / Profile preview

Manoira

Ownership: Private
Development stage: Other

Overview

Manoira is developing preclinical and translational animal health therapeutics using proprietary cocrystal technology for increased stability, improved dosing, and tailored animal applications. It has a 20-year patent covering CBDA solid form technology and is also involved in joint development for veterinary evaluation of clinical-stage human molecules (e.g., AZD1656, AZD5658) in pain, inflammation, and metabolic targets.

Therapeutic areas: ImmunologyMetabolic DisordersPsychiatryGastroenterologyNeurology
Modalities: Small moleculeCannabis-derived molecule (CBDA, cannabidiolic acid)
Industry: Veterinary

Partnerships

Conduit Pharmaceuticals

Beyond the preview

Go deeper on Manoira.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manoira.

Explore the full profile